title: Advanced chondrosarcomas: role of chemotherapy and survival.
abstract: BACKGROUND
  There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas.
  
  
  METHODS
  The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed.
  
  
  RESULTS
  Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) ≥2, number of metastatic sites ≥1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS.
  
  
  CONCLUSIONS
  Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.
authors.affiliation: Department of Medical Oncology, Institut Bergonié, Bordeaux.
authors.forename: A
authors.initials: A
authors.lastname: Italiano
authors.forename: O
authors.initials: O
authors.lastname: Mir
authors.forename: A
authors.initials: A
authors.lastname: Cioffi
authors.forename: E
authors.initials: E
authors.lastname: Palmerini
authors.forename: S
authors.initials: S
authors.lastname: Piperno-Neumann
authors.forename: C
authors.initials: C
authors.lastname: Perrin
authors.forename: L
authors.initials: L
authors.lastname: Chaigneau
authors.forename: N
authors.initials: N
authors.lastname: Penel
authors.forename: F
authors.initials: F
authors.lastname: Duffaud
authors.forename: J E
authors.initials: JE
authors.lastname: Kurtz
authors.forename: O
authors.initials: O
authors.lastname: Collard
authors.forename: F
authors.initials: F
authors.lastname: Bertucci
authors.forename: E
authors.initials: E
authors.lastname: Bompas
authors.forename: A
authors.initials: A
authors.lastname: Le Cesne
authors.forename: R G
authors.initials: RG
authors.lastname: Maki
authors.forename: I
authors.initials: I
authors.lastname: Ray Coquard
authors.forename: J Y
authors.initials: JY
authors.lastname: Blay
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002813:Chondrosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D018943:Anthracyclines
keywords: chemotherapy; chondrosarcoma; prognosis; treatment